To combat malaria and other mosquito-borne diseases, researchers propose an innovative strategy: using a human-approved drug to render blood lethal to mosquitoes. Published in *Science Translational Medicine*, a study highlights nitisinone—a medication already FDA-approved for rare genetic disorders—as a potential tool to disrupt disease transmission. When administered in low doses, nitisinone makes human blood toxic to mosquitoes, killing them within hours of feeding. This effect persists for up to 16 days, offering prolonged protection.
Though nitisinone doesn’t prevent malaria infection, it targets mosquito populations by preventing blood-fed females from laying eggs, potentially collapsing local transmission cycles. This approach mirrors herd immunity, relying on community-wide use to suppress outbreaks rather than individual protection.
Mosquitoes cause over 600,000 deaths annually, primarily through malaria. Current tools like bed nets, insecticides, and vaccines remain critical, but resistance in mosquito populations limits their efficacy. Nitisinone could complement these methods, particularly in high-resistance areas. Researchers stress it isn’t a standalone solution but part of an integrated strategy.
Álvaro Acosta Serrano, a study coauthor, emphasizes the advantage of repurposing an existing, vetted drug, accelerating potential deployment. While challenges like dosing protocols and community adoption remain, the approach offers a promising pathway to reduce disease burden. By transforming humans into unintentional agents of mosquito control, this method could help break the deadly link between mosquitoes and vulnerable populations, marking a novel step in global health efforts.
